

Won Seog Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4981113/publications.pdf>

Version: 2024-02-01

496
papers

14,057
citations

31976

53
h-index

38395

95
g-index

585
all docs

585
docs citations

585
times ranked

13232
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4410-4416.	1.6	532
2	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 229-240.	13.7	517
3	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	1.4	512
4	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 155-165.	1.6	488
5	A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 371-375.	21.4	326
6	Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3898-3905.	1.6	320
7	Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 6027-6032.	1.6	312
8	A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 389-400.	10.7	285
9	Measuring Response in Solid Tumors: Comparison of RECIST and WHO Response Criteria. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 533-537.	1.3	195
10	Phase I study of dexamethasone, methotrexate, ifosfamide, asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. <i>Cancer Science</i> , 2008, 99, 1016-1020.	3.9	193
11	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
12	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	1.6	160
13	DeSUMOylating isopeptidase: a second class of SUMO protease. <i>EMBO Reports</i> , 2012, 13, 339-346.	4.5	153
14	Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2103-2109.	1.6	149
15	Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. <i>Annals of Hematology</i> , 2007, 86, 493-498.	1.8	137
16	Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type. <i>Oncotarget</i> , 2015, 6, 17764-17776.	1.8	136
17	Type II enteropathy-associated T-cell lymphoma: A multicenter analysis from the Asia Lymphoma Study Group. <i>American Journal of Hematology</i> , 2012, 87, 663-668.	4.1	134
18	Autologous Hematopoietic Stem Cell Transplantation in Extranodal Natural Killer/T Cell Lymphoma: A Multinational, Multicenter, Matched Controlled Study. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1356-1364.	2.0	133

#	ARTICLE	IF	CITATIONS
19	Phase II Study of High-Dose Lovastatin in Patients with Advanced Gastric Adenocarcinoma. <i>Investigational New Drugs</i> , 2001, 19, 81-83.	2.6	123
20	Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. <i>Human Gene Therapy</i> , 2001, 12, 671-684.	2.7	123
21	Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. <i>Blood</i> , 2011, 117, 1958-1965.	1.4	121
22	Concurrent chemoradiotherapy followed by l-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. <i>Annals of Hematology</i> , 2014, 93, 1895-1901.	1.8	115
23	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	12.8	107
24	A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. <i>British Journal of Haematology</i> , 2014, 165, 768-776.	2.5	104
25	Docetaxel 75 mg/m ² is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, 248-254.	1.3	103
26	Primary Pulmonary Non-Hodgkin's Lymphoma. <i>Japanese Journal of Clinical Oncology</i> , 2004, 34, 510-514.	1.3	103
27	Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study. <i>American Journal of Hematology</i> , 2020, 95, 362-371.	4.1	102
28	Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. <i>Blood</i> , 2011, 117, 1291-1300.	1.4	94
29	Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. <i>Neuro-Oncology</i> , 2010, 12, 289-296.	1.2	90
30	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	3.5	90
31	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
32	Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. <i>Blood</i> , 2019, 133, 137-146.	1.4	88
33	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	1.4	86
34	TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1-7.	2.8	85
35	Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis. <i>Lancet Haematology</i> , 2015, 2, e66-e74.	4.6	85
36	Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2004, 54, 385-390.	2.3	83

#	ARTICLE	IF	CITATIONS
37	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	4.6	83
38	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
39	Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1597-1604.	2.0	76
40	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. <i>Haematologica</i> , 2016, 101, 757-763.	3.5	75
41	Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study. <i>Blood</i> , 2020, 136, 2754-2763.	1.4	74
42	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e362-e373.	4.6	70
43	Aggressive natural killer cell leukemia: Therapeutic potential of asparaginase and allogeneic hematopoietic stem cell transplantation. <i>Cancer Science</i> , 2012, 103, 1079-1083.	3.9	67
44	Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma study group. <i>Journal of Hematology and Oncology</i> , 2013, 6, 86.	17.0	67
45	Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus Positive and Negative Relapsed or Refractory Non-Hodgkin Lymphomas. <i>Cancer Research and Treatment</i> , 2019, 51, 611-622.	3.0	66
46	Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. <i>Clinical Immunology</i> , 2007, 125, 257-267.	3.2	64
47	Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. <i>Haematologica</i> , 2017, 102, 903-909.	3.5	64
48	Importance of open lung biopsy in the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. <i>American Journal of Hematology</i> , 2002, 71, 75-79.	4.1	63
49	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	1.3	63
50	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. <i>Blood Research</i> , 2015, 50, 254.	1.3	60
51	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , 2021, 5, 2577-2585.	5.2	60
52	A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. <i>Oncology Reports</i> , 2006, 16, 1117-21.	2.6	60
53	Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients. <i>Annals of Hematology</i> , 2015, 94, 71-78.	1.8	58
54	Curcumin inhibits interferon- γ induced NF- κ B and COX-2 in human A549 non-small cell lung cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2005, 334, 313-318.	2.1	56

#	ARTICLE	IF	CITATIONS
55	Epsteinâ€“Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1. <i>Leukemia and Lymphoma</i> , 2012, 53, 1586-1591.	1.3	55
56	The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in <i>TNFAIP3</i> followed by mutations in <i>TBL1XR1</i> and <i>CREBBP</i> . <i>Oncotarget</i> , 2017, 8, 17038-17049.	1.8	55
57	Genome-wide array-based comparative genomic hybridization of ocular marginal zone B cell lymphoma: Comparison with pulmonary and nodal marginal zone B cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 776-783.	2.8	54
58	Pulmonary marginal zone B-cell lymphoma of MALT typeâ€“What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. <i>Annals of Hematology</i> , 2010, 89, 563-568.	1.8	54
59	Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2005, 13, 859-64.	2.6	54
60	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	1.4	53
61	Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. <i>Investigational New Drugs</i> , 2013, 31, 469-472.	2.6	51
62	Intestinal Lymphoma: Exploration of the Prognostic Factors and the Optimal Treatment. <i>Leukemia and Lymphoma</i> , 2004, 45, 339-344.	1.3	50
63	Treatment of localized extranodal NK/T cell lymphoma, nasal type. <i>International Journal of Hematology</i> , 2010, 92, 690-696.	1.6	50
64	Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. <i>Annals of Hematology</i> , 2012, 91, 543-551.	1.8	50
65	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. <i>Lancet Haematology</i> , 2015, 2, e326-e333.	4.6	50
66	Prognostic significance of anatomic subsites: Results of radiation therapy for 66 patients with localized orbital marginal zone B cell lymphoma. <i>Radiotherapy and Oncology</i> , 2009, 90, 236-241.	0.6	49
67	Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes. <i>Annals of Hematology</i> , 2011, 90, 1391-1398.	1.8	49
68	Genetic risk of extranodal natural killer T-cell lymphoma: a genome-wide association study in multiple populations. <i>Lancet Oncology</i> , 2020, 21, 306-316.	10.7	49
69	Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type. <i>Clinical Cancer Research</i> , 2007, 13, 3250-3254.	7.0	48
70	Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population. <i>Thrombosis Research</i> , 2012, 130, e6-e12.	1.7	48
71	Integrated copy number and gene expression profiling analysis of Epsteinâ€“Barr virusâ€“positive diffuse large B-cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 383-396.	2.8	48
72	Aggressive natural killer cell leukemia: clinical features and treatment outcome. <i>Haematologica</i> , 2002, 87, 1343-5.	3.5	48

#	ARTICLE	IF	CITATIONS
73	Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 463-468.	2.0	47
74	Matchedâ€pair analysis comparing the outcomes of primary breast and nodal diffuse large Bâ€cell lymphoma in patients treated with rituximab plus chemotherapy. <i>International Journal of Cancer</i> , 2012, 131, 235-243.	5.1	47
75	Effect of Nutritional Status on Survival Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP. <i>Nutrition and Cancer</i> , 2014, 66, 225-233.	2.0	47
76	Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study. <i>Lancet Oncology</i> , The, 2021, 22, 1740-1751.	10.7	46
77	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018, 36, 7507-7507.	1.6	45
78	Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classificationâ€Based Prognostic Scoring System (WPSS) and comparison with IPSS. <i>European Journal of Haematology</i> , 2008, 81, 364-373.	2.2	44
79	Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. <i>Annals of Hematology</i> , 2006, 85, 781-786.	1.8	43
80	CD79B and MYD88 mutations in diffuse large B-cell lymphoma. <i>Human Pathology</i> , 2014, 45, 556-564.	2.0	43
81	A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients. <i>Haematologica</i> , 2015, 100, e505-e507.	3.5	43
82	Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review. <i>Journal of Hematology and Oncology</i> , 2018, 11, 140.	17.0	43
83	Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma. <i>Annals of Hematology</i> , 2019, 98, 2541-2550.	1.8	43
84	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	4.1	43
85	EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood. <i>Korean Journal of Pathology</i> , 2013, 47, 137.	1.3	42
86	Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma. <i>Leukemia</i> , 2020, 34, 3413-3419.	7.2	42
87	Docetaxel Plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil-Based Regimen. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 477-480.	1.3	41
88	Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. <i>American Journal of Hematology</i> , 2007, 82, 446-452.	4.1	41
89	Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. <i>Leukemia Research</i> , 2007, 31, 359-364.	0.8	41
90	Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial. <i>Annals of Hematology</i> , 2015, 94, 1845-1851.	1.8	41

#	ARTICLE	IF	CITATIONS
91	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	3.5	41
92	Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. <i>Journal of Hematology and Oncology</i> , 2021, 14, 25.	17.0	41
93	Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 10-14.	2.3	40
94	The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 937-940.	4.1	40
95	Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm. <i>Oncotarget</i> , 2017, 8, 22014-22022.	1.8	40
96	Consideration of aggressive therapeutic strategies for primary testicular lymphoma. <i>American Journal of Hematology</i> , 2007, 82, 840-845.	4.1	39
97	Epstein-Barr virus latent membrane protein 1 increases genomic instability through Egr-1-mediated up-regulation of activation-induced cytidine deaminase in B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 2035-2040.	1.3	37
98	CD79B limits response of diffuse large B cell lymphoma to ibrutinib. <i>Leukemia and Lymphoma</i> , 2016, 57, 1413-1422.	1.3	37
99	Tuberculosis in Hematopoietic Stem Cell Transplant Recipients in Korea. <i>International Journal of Hematology</i> , 2004, 79, 185-188.	1.6	36
100	¹⁸ F-FDG uptake and its clinical relevance in primary gastric lymphoma. <i>Hematological Oncology</i> , 2010, 28, 57-61.	1.7	36
101	Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis. <i>Annals of Hematology</i> , 2016, 95, 325-335.	1.8	36
102	Atypical presentations of MERS-CoV infection in immunocompromised hosts. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 769-773.	1.7	36
103	Brentuximab vedotin: clinical updates and practical guidance. <i>Blood Research</i> , 2017, 52, 243.	1.3	36
104	Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). <i>Oncotarget</i> , 2016, 7, 85584-85591.	1.8	36
105	Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched sibling donors in first complete remission. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 122-128.	2.0	35
106	Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 91-96.	2.3	35
107	Treatment outcome of relapsed/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 98, 346-354.	1.6	35
108	A proposal for a new staging system for extranodal natural killer T-cell lymphoma: a multicenter study from China and Asia Lymphoma Study Group. <i>Leukemia</i> , 2020, 34, 2243-2248.	7.2	35

#	ARTICLE	IF	CITATIONS
109	Optimal treatment of leptomeningeal spread in glioblastoma: analysis of risk factors and outcome. <i>Acta Neurochirurgica</i> , 2015, 157, 569-576.	1.7	34
110	Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients. <i>Journal of Infection</i> , 2016, 73, 496-505.	3.3	34
111	Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma. <i>BMC Cancer</i> , 2019, 19, 936.	2.6	34
112	Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression. <i>Modern Pathology</i> , 2020, 33, 603-615.	5.5	34
113	Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 945-953.	2.3	33
114	The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients. <i>Journal of Hematology and Oncology</i> , 2015, 8, 49.	17.0	33
115	Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. <i>Oncotarget</i> , 2016, 7, 76934-76943.	1.8	33
116	Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement. <i>Modern Pathology</i> , 2018, 31, 1418-1428.	5.5	33
117	Paclitaxel with Cisplatin as Salvage Treatment for Patients with Previously Treated Advanced Transitional Cell Carcinoma of the Urothelial Tract. <i>Neoplasia</i> , 2007, 9, 18-22.	5.3	32
118	Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". <i>Annals of Hematology</i> , 2009, 88, 111-119.	1.8	32
119	Changes of Hepatitis B Virus Serologic Status after Allogeneic Hematopoietic Stem Cell Transplantation and Impact of Donor Immunity on Hepatitis B Virus. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1630-1637.	2.0	32
120	Non-bacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. <i>Leukemia and Lymphoma</i> , 2012, 53, 1515-1524.	1.3	32
121	The effect of pre-irradiation dose intense CHOP on anthracycline resistance in localized nasal NK/T-cell lymphoma. <i>Haematologica</i> , 2006, 91, 427-8.	3.5	32
122	Aggressive Natural Killer Cell Leukemia: Is Epstein-Barr Virus Negativity an Indicator of a Favorable Prognosis?. <i>Acta Haematologica</i> , 2008, 120, 199-206.	1.4	31
123	Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. <i>Medical Oncology</i> , 2009, 26, 186-192.	2.5	30
124	Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1020-1026.	1.3	30
125	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
126	Pulmonary Complications After Hematopoietic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2006, 21, 406.	2.5	29

#	ARTICLE	IF	CITATIONS
127	Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome. <i>Annals of Hematology</i> , 2009, 88, 639-645.	1.8	29
128	DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. <i>Annals of Hematology</i> , 2014, 93, 99-105.	1.8	29
129	Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism. <i>Cancer Research and Treatment</i> , 2016, 48, 312-321.	3.0	29
130	PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells. <i>Molecular Therapy</i> , 2022, 30, 579-592.	8.2	29
131	Rituximab-induced acute thrombocytopenia: a case report and review of the literature. <i>Medical Oncology</i> , 2009, 26, 45-48.	2.5	28
132	Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 677-683.	0.8	28
133	l-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia. <i>Journal of Hematology and Oncology</i> , 2016, 9, 41.	17.0	28
134	Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose. <i>Investigational New Drugs</i> , 2015, 33, 942-953.	2.6	27
135	Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 120.	2.6	27
136	Clinical characteristics, pathological distribution, and prognostic factors in non-Hodgkin lymphoma of Waldeyer's ring: nationwide Korean study. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 352.	1.7	27
137	Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. <i>Annals of Hematology</i> , 2011, 90, 539-546.	1.8	26
138	Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Cancer Science</i> , 2015, 106, 186-193.	3.9	26
139	Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labelled Phase II Trial. <i>Cancer Research and Treatment</i> , 2020, 52, 374-387.	3.0	26
140	Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2009, 114, 2688-2688.	1.4	26
141	Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). <i>Blood</i> , 2016, 128, 470-470.	1.4	25
142	Clinical features and prognostic relevance of ovarian involvement in non-Hodgkin's lymphoma: A Consortium for Improving Survival of Lymphoma (CISL) report. <i>Leukemia Research</i> , 2010, 34, 1175-1179.	0.8	24
143	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
144	Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	3.5	24

#	ARTICLE	IF	CITATIONS
145	A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study. <i>Annals of Hematology</i> , 2020, 99, 2095-2104.	1.8	24
146	Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients. <i>Acta Haematologica</i> , 2014, 131, 193-199.	1.4	23
147	Iron deficient erythropoiesis might play key role in development of anemia in cancer patients. <i>Oncotarget</i> , 2015, 6, 42803-42812.	1.8	23
148	Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 480-486.	1.7	23
149	Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 76231-76240.	1.8	23
150	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. <i>International Journal of Hematology</i> , 2010, 91, 456-463.	1.6	22
151	Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. <i>Leukemia and Lymphoma</i> , 2019, 60, 2237-2246.	1.3	22
152	Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF- κ B and Btk. <i>Oncotarget</i> , 2017, 8, 5361-5370.	1.8	22
153	Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 88-94.	1.3	21
154	Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea. <i>Annals of Hematology</i> , 2009, 88, 1099-1106.	1.8	21
155	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. <i>Leukemia and Lymphoma</i> , 2009, 50, 1119-1125.	1.3	21
156	Primary Cutaneous Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder-2 Cases With Unusual, Prolonged Clinical Course. <i>American Journal of Dermatopathology</i> , 2010, 32, 832-836.	0.6	21
157	Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 383-388.	1.6	21
158	Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy. <i>Liver International</i> , 2015, 35, 2363-2369.	3.9	21
159	Impact of fear of cancer recurrence on survival among lymphoma patients. <i>Psycho-Oncology</i> , 2020, 29, 364-372.	2.3	21
160	Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas. <i>Experimental Hematology and Oncology</i> , 2021, 10, 33.	5.0	21
161	FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 2466-2476.	1.8	21
162	Egr-1, a new downstream molecule of Epstein-Barr virus latent membrane protein 1. <i>FEBS Letters</i> , 2007, 581, 623-628.	2.8	20

#	ARTICLE	IF	CITATIONS
163	Gene mutation profiles and prognostic implications in Korean patients with T-lymphoblastic leukemia. <i>Annals of Hematology</i> , 2013, 92, 635-644.	1.8	20
164	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. <i>Nutrition</i> , 2017, 36, 67-71.	2.4	20
165	Final Analysis of the Ro-CHOP Phase III Study (Conducted by LYSA): Romidepsin Plus CHOP in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 32-33.	1.4	20
166	Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2018, 50, 1051-1063.	3.0	20
167	Treatment Outcome and Prognostic Factors in Patients with Precursor B and T Lymphoblastic Lymphoma. <i>Blood</i> , 2008, 112, 3601-3601.	1.4	20
168	Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. <i>Annals of Hematology</i> , 2006, 85, 285-290.	1.8	19
169	Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. <i>Cancer Letters</i> , 2007, 258, 90-97.	7.2	19
170	Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. <i>International Journal of Hematology</i> , 2013, 97, 403-408.	1.6	19
171	Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. <i>Annals of Hematology</i> , 2014, 93, 437-447.	1.8	19
172	Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 392-398.	2.4	19
173	Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-cell Project, an international, cooperative study. <i>Hematological Oncology</i> , 2017, 35, 630-636.	1.7	19
174	Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell Lymphoma. <i>Cancer Research and Treatment</i> , 2018, 50, 575-581.	3.0	19
175	The Efficacy of JAK2 Inhibitor in Heavily Pretreated Classical Hodgkin Lymphoma: A Prospective Pilot Study of Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 1820-1820.	1.4	19
176	Oxaliplatin and UFT Combination Chemotherapy in Patients With Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 354-357.	1.3	18
177	CHOP followed by involved field radiotherapy for localized primary gastric diffuse large B-cell lymphoma: Results of a multi center phase II study and quality of life evaluation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1253-1259.	1.3	18
178	Systemic EBV+ T-cell lymphoma in elderly patients: comparison with children and young adult patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 453, 155-163.	2.8	18
179	SNARK, a novel downstream molecule of EBV latent membrane protein 1, is associated with resistance to cancer cell death. <i>Leukemia and Lymphoma</i> , 2008, 49, 1392-1398.	1.3	18
180	Depletion of ascorbic acid alternating with its supplementation in the treatment of patients with acute myeloid leukemia or myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2009, 83, 108-118.	2.2	18

#	ARTICLE	IF	CITATIONS
181	11C-Methionine PET/CT and MRI of Primary Central Nervous System Diffuse Large B-cell Lymphoma Before and After High-Dose Methotrexate. <i>Clinical Nuclear Medicine</i> , 2012, 37, e241-e244.	1.3	18
182	Isolation of Side Population Cells in B-Cell Non-Hodgkin's Lymphomas. <i>Acta Haematologica</i> , 2013, 129, 10-17.	1.4	18
183	Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	18
184	Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy. <i>Cancer Science</i> , 2018, 109, 2056-2062.	3.9	18
185	Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation. <i>Oncotarget</i> , 2016, 7, 59892-59901.	1.8	18
186	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. <i>Investigational New Drugs</i> , 2012, 30, 368-375.	2.6	17
187	Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea. <i>Acta Haematologica</i> , 2014, 131, 18-27.	1.4	17
188	Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma. <i>BMC Cancer</i> , 2019, 19, 1080.	2.6	17
189	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	17.0	17
190	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2020, 136, 2548-2556.	1.4	17
191	Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Oncotarget</i> , 2017, 8, 13782-13791.	1.8	17
192	Clonal relationships in recurrent B-cell lymphomas. <i>Oncotarget</i> , 2016, 7, 12359-12371.	1.8	17
193	Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 890-899.	1.7	17
194	Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. <i>Journal of Clinical Oncology</i> , 2022, 40, 4261-4275.	1.6	17
195	A Case of Deep Vein Thrombosis and Pulmonary Thromboembolism after Intravenous Immunoglobulin Therapy. <i>Journal of Korean Medical Science</i> , 2007, 22, 758.	2.5	16
196	Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas. <i>Clinical Neurology and Neurosurgery</i> , 2009, 111, 748-751.	1.4	16
197	Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. <i>Cellular Signalling</i> , 2010, 22, 1858-1863.	3.6	16
198	Primary Thyroid Marginal Zone B-Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type: Clinical Manifestation and Outcome of a Rare Disease - Consortium for Improving Survival of Lymphoma Study. <i>Acta Haematologica</i> , 2012, 127, 100-104.	1.4	16

#	ARTICLE	IF	CITATIONS
199	Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma. <i>Blood Research</i> , 2014, 49, 15.	1.3	16
200	Health-related quality of life in Korean lymphoma survivors compared with the general population. <i>Annals of Hematology</i> , 2014, 93, 1531-1540.	1.8	16
201	Weekly rituximab consolidation following four cycles of CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL). <i>European Journal of Haematology</i> , 2015, 94, 504-510.	2.2	16
202	Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis. <i>Annals of Hematology</i> , 2018, 97, 1437-1443.	1.8	16
203	Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 3971-3980.	3.9	16
204	First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. <i>Cancers</i> , 2020, 12, 2192.	3.7	16
205	Interferon-alpha resistance can be reversed by inhibition of IFN-alpha-induced COX-2 expression potentially via STAT1 activation in A549 cells. <i>Oncology Reports</i> , 2006, 15, 1541-9.	2.6	16
206	Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. <i>Investigational New Drugs</i> , 2010, 28, 516-522.	2.6	15
207	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphomas Involving Rare Extranodal Sites: A Single-Center Experience. <i>Acta Haematologica</i> , 2010, 123, 48-54.	1.4	15
208	Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 157-163.	1.6	15
209	Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 6062.	3.3	15
210	Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study. <i>Blood Research</i> , 2015, 50, 242.	1.3	15
211	Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas. <i>Annals of Hematology</i> , 2020, 99, 1293-1302.	1.8	15
212	A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1953-1953.	1.4	15
213	A Phase 1 Dose Escalation Study of Igm-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies. <i>Blood</i> , 2021, 138, 132-132.	1.4	15
214	High incidence of mucosa-associated lymphoid tissue in primary thyroid lymphoma: A clinicopathologic study of 18 cases in the Korean population. <i>Leukemia and Lymphoma</i> , 2006, 47, 2128-2131.	1.3	14
215	Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease. <i>European Journal of Haematology</i> , 2007, 79, 287-291.	2.2	14
216	Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells. <i>Leukemia Research</i> , 2012, 36, 1172-1178.	0.8	14

#	ARTICLE	IF	CITATIONS
217	Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: Results from a prospective cohort study. <i>Annals of Hematology</i> , 2012, 91, 1747-1756.	1.8	14
218	Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. <i>Blood Research</i> , 2013, 48, 171.	1.3	14
219	Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma. <i>International Journal of Hematology</i> , 2016, 104, 591-595.	1.6	14
220	Macrophage inflammatory protein 1 alpha (MIP-1 α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma. <i>Hematological Oncology</i> , 2017, 35, 310-316.	1.7	14
221	IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. <i>Journal of Cancer</i> , 2017, 8, 1018-1024.	2.5	14
222	CXCR4 can induce PI3K inhibitor resistance in ABC DLBCL. <i>Blood Cancer Journal</i> , 2018, 8, 23.	6.2	14
223	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. <i>Bone Marrow Transplantation</i> , 2018, 53, 967-976.	2.4	14
224	Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk. <i>Blood Advances</i> , 2020, 4, 868-879.	5.2	14
225	Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study. <i>Oncotarget</i> , 2016, 7, 72033-72043.	1.8	14
226	Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 448-457.	3.0	14
227	Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors. <i>Cancer Research and Treatment</i> , 2018, 50, 204-211.	3.0	14
228	Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. <i>International Journal of Hematology</i> , 2010, 92, 510-517.	1.6	13
229	Aggressive B cell lymphomas of the gastrointestinal tract: clinicopathologic and genetic analysis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 495-502.	2.8	13
230	Endoscopic Findings in Mantle Cell Lymphoma with Gastrointestinal Tract Involvement. <i>Acta Haematologica</i> , 2012, 127, 129-134.	1.4	13
231	The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms. <i>Annals of Hematology</i> , 2018, 97, 2363-2372.	1.8	13
232	Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 1205-1208.	2.4	13
233	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 628807.	2.8	13
234	The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. <i>Anticancer Research</i> , 2015, 35, 2465-74.	1.1	13

#	ARTICLE	IF	CITATIONS
235	Microarray Gene-expression Profiling Analysis Comparing PCNSL and Non-CNS Diffuse Large B-Cell Lymphoma. <i>Anticancer Research</i> , 2015, 35, 3333-40.	1.1	13
236	Locoregional Response and Increased Natural Killer Activity after Intratumoral Injection of HLA-B7/12-Microglobulin Gene in Patients with Cancer. <i>Human Gene Therapy</i> , 1998, 9, 2031-2038.	2.7	12
237	A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas. <i>The Korean Journal of Hematology</i> , 2012, 47, 53.	0.7	12
238	Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia. <i>OncoTargets and Therapy</i> , 2014, 7, 1717.	2.0	12
239	Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky038.	2.9	12
240	Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 317-325.	1.3	12
241	Phase II study of R ² CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. <i>Cancer Communications</i> , 2019, 39, 1-10.	9.2	12
242	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	3.3	12
243	Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma. <i>Cancers</i> , 2020, 12, 3548.	3.7	12
244	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	1.8	12
245	A Phase 2 Study of Panobinostat (PAN) in Combination with Bortezomib (BTZ) in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL). <i>Blood</i> , 2014, 124, 503-503.	1.4	12
246	Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2017, 8, 92171-92182.	1.8	12
247	Promoter methylation and down-regulation of DAPK is associated with gastric atrophy. <i>International Journal of Molecular Medicine</i> , 2003, 12, 827-30.	4.0	12
248	Production of IL-12 from gene modified human dermal fibroblasts: A preclinical study for IL-12 cancer gene therapy. <i>Experimental and Molecular Medicine</i> , 1997, 29, 65-69.	7.7	11
249	A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2010, 91, 886-891.	1.6	11
250	Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2011, 29, 154-160.	2.6	11
251	Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2012, 53, 807-811.	1.3	11
252	Bone involvement in patients with stage IV diffuse large B-cell lymphoma: does it have a prognostic value?. <i>Leukemia and Lymphoma</i> , 2012, 53, 173-175.	1.3	11

#	ARTICLE	IF	CITATIONS
253	Clinical features and outcomes of Hodgkin's lymphoma in Korea: Consortium for Improving Survival of Lymphoma (CISL). <i>Annals of Hematology</i> , 2012, 91, 223-233.	1.8	11
254	Primary cardiac lymphoma mimicking infiltrative cardiomyopathy. <i>European Journal of Heart Failure</i> , 2013, 15, 589-591.	7.1	11
255	Matched-Pair Analysis Comparing the Outcomes of T Cell/Histiocyte-Rich Large B Cell Lymphoma and Diffuse Large B Cell Lymphoma in Patients Treated with Rituximab-CHOP. <i>Acta Haematologica</i> , 2014, 131, 156-161.	1.4	11
256	Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator. <i>Haematologica</i> , 2015, 100, e106-e109.	3.5	11
257	KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study. <i>Human Immunology</i> , 2015, 76, 636-643.	2.4	11
258	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas. <i>Blood Research</i> , 2016, 51, 181.	1.3	11
259	Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability. <i>Annals of Hematology</i> , 2016, 95, 581-591.	1.8	11
260	Use of complementary and alternative medicine by lymphoma survivors in South Korea. <i>European Journal of Oncology Nursing</i> , 2018, 33, 91-96.	2.1	11
261	Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma. <i>Cytokine</i> , 2019, 113, 371-379.	3.2	11
262	Validation of the Marginal Zone Lymphoma International Prognostic Index. <i>Annals of Hematology</i> , 2019, 98, 457-464.	1.8	11
263	The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 3-5.	1.4	11
264	Pharmacokinetic and Safety of CT-P10, a Biosimilar Candidate to the Rituximab Reference Product, in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2016, 128, 1807-1807.	1.4	11
265	Sexuality and Quality of Life after Hematopoietic Stem Cell Transplantation. <i>Korean Journal of Internal Medicine</i> , 2002, 17, 19-23.	1.7	11
266	Primary gastric lymphoma of T-cell origin: Clinicopathologic features and treatment outcome. <i>Leukemia Research</i> , 2006, 30, 1253-1258.	0.8	10
267	Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. <i>American Journal of Hematology</i> , 2009, 84, 826-829.	4.1	10
268	Clinical features and treatment outcomes of lymphoplasmacytic lymphoma: a single center experience in Korea. <i>Annals of Hematology</i> , 2010, 89, 1011-1018.	1.8	10
269	Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. <i>Investigational New Drugs</i> , 2010, 28, 171-177.	2.6	10
270	Hodgkin's Lymphoma Arising in a Patient With Hypersensitivity to Mosquito Bites: A Case Report. <i>Journal of Clinical Oncology</i> , 2010, 28, e148-e150.	1.6	10

#	ARTICLE	IF	CITATIONS
271	Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 865-873.	2.3	10
272	Looking to the future and learning lessons from the recent past: changing stakeholder perceptions of biosimilars in cancer. <i>Future Oncology</i> , 2017, 13, 17-29.	2.4	10
273	Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma. <i>Annals of Hematology</i> , 2018, 97, 1427-1436.	1.8	10
274	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 1618-1618.	1.4	10
275	Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1595-1595.	1.4	10
276	Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study. <i>Blood</i> , 2019, 134, 4081-4081.	1.4	10
277	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. <i>Blood</i> , 2014, 124, 1718-1718.	1.4	10
278	Treatment Outcomes of Rituximab Plus Hyper-CVAD in Korean Patients with Sporadic Burkitt or Burkitt-like Lymphoma: Results of a Multicenter Analysis. <i>Cancer Research and Treatment</i> , 2015, 47, 173-181.	3.0	10
279	Renal Insufficiency in newly-diagnosed multiple myeloma: analysis according to International Myeloma Working Group consensus statement. <i>Anticancer Research</i> , 2014, 34, 4299-306.	1.1	10
280	A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 27-33.	2.3	9
281	Frontal Sinus Lymphoma Presenting As Progressive Multiple Cranial Nerve Palsy. <i>Yonsei Medical Journal</i> , 2011, 52, 1044.	2.2	9
282	A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas. <i>Investigational New Drugs</i> , 2013, 31, 1514-1521.	2.6	9
283	Platelet to lymphocyte ratio (PLR) retains independent prognostic significance in advanced stage marginal zone lymphoma patients treated with rituximab, cyclophosphamide, vincristine, and prednisone combination chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma trial. <i>Blood Research</i> , 2017, 52, 200.	1.3	9
284	Efficacy of intravenous iron treatment for chemotherapy-induced anemia: A prospective Phase II pilot clinical trial in South Korea. <i>PLoS Medicine</i> , 2020, 17, e1003091.	8.4	9
285	Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β_2 -microglobulin Levels. <i>Cancer Research and Treatment</i> , 2021, 53, 847-856.	3.0	9
286	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. <i>BMC Cancer</i> , 2021, 21, 82.	2.6	9
287	Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 547-555.	3.0	9
288	Excessive Toxicity of Once Daily Intravenous Busulfan, Melphalan, and Thiotepa Followed by Autologous Stem Cell Transplantation On Patients with Non-Hodgkin's Lymphoma.. <i>Blood</i> , 2009, 114, 4361-4361.	1.4	9

#	ARTICLE	IF	CITATIONS
289	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. Journal of Clinical Oncology, 2022, 40, 7503-7503.	1.6	9
290	Real-World Efficacy of 5-Azacytidine as Salvage Chemotherapy for Angioimmunoblastic T-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, e972-e980.	0.4	9
291	Stage IV marginal zone B-cell lymphoma " prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Science, 2010, 101, 2443-2447.	3.9	8
292	Extranodal natural killer/T-cell lymphoma with long-term survival and repeated relapses: does it indicate the presence of indolent subtype?. The Korean Journal of Hematology, 2012, 47, 202.	0.7	8
293	Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea. International Journal of Hematology, 2015, 101, 273-278.	1.6	8
294	Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update. F1000Research, 2016, 5, 1933.	1.6	8
295	A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 2274-2284.	6.4	8
296	Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma. Cytokine, 2020, 129, 155048.	3.2	8
297	A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis. Annals of Hematology, 2020, 99, 1283-1291.	1.8	8
298	Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis. Hematological Oncology, 2021, 39, 664-673.	1.7	8
299	Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies. Blood, 2019, 134, 4009-4009.	1.4	8
300	A Phase 1 Study of the Combination of MG4101, Ex Vivo-Expanded Allogeneic NK Cells and Rituximab for Relapsed or Refractory Non-Hodgkin Lymphoma. Blood, 2020, 136, 14-15.	1.4	8
301	Asian variant of intravascular large B-cell lymphoma: a comparison of clinical features based on involvement of the central nervous system. Korean Journal of Internal Medicine, 2020, 35, 946-956.	1.7	8
302	Quality of life one year after chemoradiotherapy for localized primary gastric diffuse large B-cell lymphoma. Medical Oncology, 2008, 25, 447-450.	2.5	7
303	A retrospective study to compare two methotrexate-based regimens for primary central nervous system lymphoma. Leukemia and Lymphoma, 2009, 50, 1110-1118.	1.3	7
304	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. Annals of Hematology, 2011, 90, 1409-1418.	1.8	7
305	Pilot Trial of Systemic Methotrexate plus R-CHOP Regimen with Intrathecal Methotrexate for Simultaneous Central Nervous System and Systemic Diffuse Large B Cell Lymphoma. Acta Haematologica, 2015, 133, 179-182.	1.4	7
306	Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study. Annals of Hematology, 2016, 95, 603-611.	1.8	7

#	ARTICLE	IF	CITATIONS
307	Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers. <i>Blood Cancer Journal</i> , 2017, 7, 653.	6.2	7
308	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. <i>International Journal of Hematology</i> , 2019, 110, 438-446.	1.6	7
309	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016. <i>Medicine (United States)</i> , 2019, 98, e17641.	1.0	7
310	Comparison of the Lymph2Cx Assay and Hans Algorithm in Determining the Cell-of-Origin of Diffuse Large B-Cell Lymphomas, Not Otherwise Specified. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020, 28, 731-740.	1.2	7
311	Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	1.4	7
312	Clinical Features and Treatment Outcomes of Non-Hodgkin's Lymphoma with Breast Involvement; Multi-Institutional Analysis of 98 Patients in Korea.. <i>Blood</i> , 2009, 114, 5024-5024.	1.4	7
313	Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. <i>International Journal of Hematology</i> , 2005, 81, 258-263.	1.6	6
314	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2005, 35, 214-217.	1.3	6
315	Postremission therapy for acute myeloid leukemia in the first remission. <i>Leukemia and Lymphoma</i> , 2007, 48, 937-943.	1.3	6
316	Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B-cell lymphoma with secondary central nervous system involvement. <i>International Journal of Hematology</i> , 2015, 102, 678-688.	1.6	6
317	Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma. <i>Acta Haematologica</i> , 2016, 136, 186-190.	1.4	6
318	Clinical development of CT-P10 and other biosimilar cancer therapeutics. <i>Future Oncology</i> , 2017, 13, 31-44.	2.4	6
319	Clinical impact of CD5 expression in Korean patients with diffuse large B-cell lymphoma. <i>Blood Research</i> , 2017, 52, 193.	1.3	6
320	Association between sexuality knowledge and sexual dysfunction in hematopoietic stem cell transplantation patients and their partners. <i>Patient Education and Counseling</i> , 2020, 103, 1630-1636.	2.2	6
321	Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing. <i>BMC Cancer</i> , 2021, 21, 972.	2.6	6
322	Imaging Features and Prognostic Value of FDG PET/CT in Patients with Intravascular Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 7289-7297.	1.9	6
323	ROCHOP study: A phase III randomized study of CHOP compared to romidepsin-CHOP in untreated peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8616-TPS8616.	1.6	6
324	Adenocarcinoma of Unknown Primary Site. <i>Korean Journal of Internal Medicine</i> , 2002, 17, 234-239.	1.7	6

#	ARTICLE	IF	CITATIONS
325	Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. <i>Cancer Research and Treatment</i> , 2019, 51, 1302-1312.	3.0	6
326	Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 200.	6.2	6
327	Vinorelbine, Ifosfamide, and Cisplatin Combination as Salvage Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 509-513.	1.3	5
328	Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 299-304.	2.3	5
329	Waldeyer's ring marginal zone B cell lymphoma: are the clinical and prognostic features nodal or extranodal? A study by the Consortium for Improving Survival of Lymphoma (CISL). <i>International Journal of Hematology</i> , 2012, 96, 631-637.	1.6	5
330	Plerixafor use for peripheral blood stem cell mobilization in Korea. <i>Blood Research</i> , 2013, 48, 72.	1.3	5
331	Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry. <i>Blood Research</i> , 2013, 48, 115.	1.3	5
332	A subset of CD45+/CD19 ⁺ cells in bone marrow may be associated with clinical outcomes of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3052-3057.	1.3	5
333	Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma. <i>Annals of Laboratory Medicine</i> , 2016, 36, 209-214.	2.5	5
334	Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 995-1001.	1.3	5
335	Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. <i>Investigational New Drugs</i> , 2018, 36, 877-885.	2.6	5
336	Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay. <i>Human Pathology</i> , 2018, 73, 51-58.	2.0	5
337	Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study. <i>Annals of Hematology</i> , 2018, 97, 1851-1857.	1.8	5
338	Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping. <i>Scientific Reports</i> , 2021, 11, 5879.	3.3	5
339	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	5
340	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	1.4	5
341	Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 4443-4443.	1.4	5
342	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2015, 126, 1493-1493.	1.4	5

#	ARTICLE	IF	CITATIONS
343	Case Match Control Analysis of Propel Reveals Survival Advantage for Patients with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) Treated with Pralatrexate. <i>Blood</i> , 2016, 128, 4149-4149.	1.4	5
344	Copanlisib in patients with relapsed or refractory follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7535-7535.	1.6	5
345	A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7563-7563.	1.6	5
346	Reply to A. Chan et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 1016-1017.	1.6	4
347	Systemic Epstein-Barr virus-negative mature natural killer-cell lymphoma with cutaneous and visceral involvement. <i>Apmis</i> , 2015, 123, 990-992.	2.0	4
348	Clinical Features and Survival of Patients With Follicular Lymphoma in Korea. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 197-202.	0.4	4
349	A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. <i>Leukemia and Lymphoma</i> , 2016, 57, 1406-1412.	1.3	4
350	A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial). <i>Leukemia and Lymphoma</i> , 2019, 60, 3251-3257.	1.3	4
351	Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. <i>Cancer Communications</i> , 2021, 41, 275-278.	9.2	4
352	Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications. <i>Antiviral Research</i> , 2021, 189, 105063.	4.1	4
353	EGR1 as a potential marker of prognosis in extranodal NK/T-cell lymphoma. <i>Scientific Reports</i> , 2021, 11, 10342.	3.3	4
354	Role of 23.4Â Gy upfront whole-brain radiation therapy following high-dose methotrexate for primary central nervous system lymphoma: a comparative analysis of whole-brain radiation therapy versus no radiation therapy. <i>Journal of Neuro-Oncology</i> , 2021, 154, 207-217.	2.9	4
355	Outcomes for Patients with High-Risk Relapsed or Refractory Indolent B-Cell Lymphoma Treated with Copanlisib in the CHRONOS-1 Study. <i>Blood</i> , 2018, 132, 395-395.	1.4	4
356	Global Phase I/III Pharmacokinetic and Efficacy Study Comparing CT-P10, a Biosimilar Candidate to the Rituximab Reference Product in Patients with Advanced Stage Follicular Lymphoma (AFL). <i>Blood</i> , 2015, 126, 5111-5111.	1.4	4
357	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8613-TPS8613.	1.6	4
358	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	1.6	4
359	Recent advances in understanding and managing T-cell lymphoma. <i>F1000Research</i> , 2017, 6, 2123.	1.6	4
360	Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma. <i>Cancer Research and Treatment</i> , 2017, 49, 92-103.	3.0	4

#	ARTICLE	IF	CITATIONS
361	Prognostic significance of serum Î²2-microglobulin levels in patients with peripheral T-cell lymphoma not otherwise specified. <i>Leukemia and Lymphoma</i> , 2021, , 1-7.	1.3	4
362	498â€¦Evorpaccept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01. , 2021, 9, A530-A530.		4
363	Clinical relevance of serum-derived exosomal messenger RNA sequencing in patients with non-Hodgkin lymphoma. <i>Journal of Cancer</i> , 2022, 13, 1388-1397.	2.5	4
364	Circulating Tumor DNAâ€™Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas. <i>Cancer Research and Treatment</i> , 2023, 55, 291-303.	3.0	4
365	Pegfilgrastim Prophylaxis is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged â‰¥75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 2021, , .	3.0	4
366	Phase 1/2 study of anbalcabtogene autoleucel, novel anti-CD19 CAR-T cell therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7522-7522.	1.6	4
367	A genomicâ€™augmented multivariate prognostic model for the survival of naturalâ€™killer/Tâ€™cell lymphoma patients from an international cohort. <i>American Journal of Hematology</i> , 2022, 97, 1159-1169.	4.1	4
368	Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2003, 33, 620-625.	1.3	3
369	Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. <i>Leukemia and Lymphoma</i> , 2011, 52, 317-320.	1.3	3
370	Dexamethasone, methotrexate, ifosfamide,l-asparaginase and etoposide (SMILE) chemotherapy for relapsed or refractory adult lymphoblastic lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2196-2198.	1.3	3
371	PKD1 is critical for Epsteinâ€™Barr virus LMP1-induced protection of malignant B cells from cell death induced by rituximab. <i>Leukemia and Lymphoma</i> , 2015, 56, 194-201.	1.3	3
372	Is there role of additional chemotherapy after definitive local treatment for stage I/II marginal zone lymphoma?: Consortium for Improving Survival of Lymphoma (CISL) study. <i>International Journal of Hematology</i> , 2015, 102, 420-425.	1.6	3
373	A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkinâ€™s lymphoma. <i>Annals of Hematology</i> , 2020, 99, 255-264.	1.8	3
374	A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score. <i>Blood Advances</i> , 2020, 4, 5762-5771.	5.2	3
375	Treatment with intravenous busulfan, melphalan, and etoposide followed by autologous stem cell transplantation in patients with nonâ€™Hodgkin's lymphoma: a multicenter study from the consortium for improving survival of lymphoma. <i>Transplant International</i> , 2020, 33, 1211-1219.	1.6	3
376	Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months. <i>Journal of Cancer</i> , 2021, 12, 2488-2497.	2.5	3
377	Role in staging and prognostic value of pretherapeutic F-18 FDG PET/CT in patients with gastric MALT lymphoma without high-grade transformation. <i>Scientific Reports</i> , 2021, 11, 9243.	3.3	3
378	Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 4241-4250.	1.9	3

#	ARTICLE	IF	CITATIONS
379	MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma. <i>Human Pathology</i> , 2021, 113, 9-19.	2.0	3
380	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	1.4	3
381	An Individualized Risk Mitigation Approach for Safety: Experience from the Mosunetuzumab (CD20/CD3) Tj ETQq1 1 0.784314 rgBT / 4728-4728.	1.4	3
382	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. <i>Blood Research</i> , 2020, 55, 85-90.	1.3	3
383	A Prognostic Index for Extranodal Natural Killer/T Cell Lymphoma after Non-Anthracycline-Based Treatment (PINK-B): Prognostic Index of Natural Killer Cell Lymphoma (PINK) Combined with Serum Beta-2 Microglobulin. <i>Blood</i> , 2016, 128, 1821-1821.	1.4	3
384	Asian Multinational Phase II Study of Darinaparsin in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1376-1376.	1.4	3
385	Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma. <i>Journal of Neuro-Oncology</i> , 2022, 156, 307-316.	2.9	3
386	A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma: Incorporation of Serum β -2-Microglobulin to PINK. <i>Cancer Research and Treatment</i> , 2023, 55, 314-324.	3.0	3
387	CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. <i>Blood Advances</i> , 2022, 6, 6120-6130.	5.2	3
388	The Outcomes of Hypertransfusion in Major ABO Incompatible Allogeneic Stem Cell Transplantation. <i>Journal of Korean Medical Science</i> , 2004, 19, 79.	2.5	2
389	What is stage II in high-grade primary gastric lymphoma?. <i>Leukemia Research</i> , 2007, 31, 1039-1043.	0.8	2
390	Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 943-946.	1.8	2
391	Indolent CD56-Positive Clonal T-Cell Lymphoproliferative Disease of the Stomach Mimicking Lymphomatoid Gastropathy. <i>Korean Journal of Pathology</i> , 2014, 48, 430-433.	1.3	2
392	Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal type. <i>International Forum of Allergy and Rhinology</i> , 2015, 5, 960-966.	2.8	2
393	The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective. <i>Blood Research</i> , 2017, 52, 3.	1.3	2
394	Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large-B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 149-156.	0.4	2
395	Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 668-678.	1.7	2
396	Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34 ⁺ cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2021, 36, 737-749.	1.3	2

#	ARTICLE	IF	CITATIONS
397	Prognostic value of single nucleotide polymorphisms for extranodal natural killer/T-cell lymphoma: the identification of risk factors in the molecular era. <i>Cancer Communications</i> , 2021, 41, 1232-1233.	9.2	2
398	Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial. <i>Blood</i> , 2018, 132, 2921-2921.	1.4	2
399	The Clinical Outcomes of Autologous Stem Cell Transplantation in Peripheral T Cell Lymphoma: from Retrospective Multicenter Study in Korea.. <i>Blood</i> , 2007, 110, 1892-1892.	1.4	2
400	A Phase I Trial of Bortezomib Plus CHOP Every 2 Weeks in Patients with Advanced Stage Diffuse Large B-Cell Lymphomas.. <i>Blood</i> , 2007, 110, 4446-4446.	1.4	2
401	The Efficacy of Bortezomib-CHOP In Patients with Advanced Stage T or NK/T Cell Lymphomas: The Results of Multicenter Phase II Study.. <i>Blood</i> , 2010, 116, 1791-1791.	1.4	2
402	Pretreatment EBV-DNA Copy Number Is Predictive for Response to SMILE Chemotherapy for Newly-Diagnosed Stage IV, Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of NKTSG Phase II Study. <i>Blood</i> , 2010, 116, 2873-2873.	1.4	2
403	Phase I Study of mTOR Inhibitor Everolimus Plus CHOP in Patients with Advanced, Aggressive T-Cell lymphomas. <i>Blood</i> , 2011, 118, 1642-1642.	1.4	2
404	Phase II Trial Of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (methotrexate, ifosfamide, etoposide, dexamethasone, and L-asparaginase) Chemotherapy For Patients With Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>Blood</i> , 2013, 122, 3037-3037.	1.4	2
405	A Multi-Center, Non-Randomized Phase 2 Study of Ofatumumab in Combination with ICE-Chemotherapy (O-ICE) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014, 124, 5465-5465.	1.4	2
406	Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study. <i>Blood</i> , 2015, 126, 256-256.	1.4	2
407	A multicenter phase II study of bendamustine with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 8023-8023.	1.6	2
408	Double-blind, randomized phase 3 study to compare efficacy and safety of the biosimilar CT-P10 to rituximab combined with CVP therapy in patients with previously untreated advanced-stage follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7532-7532.	1.6	2
409	Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 560-569.	1.7	2
410	Comparison of Prognostic Stratification between IPI, PIT, and NCCN-IPI in the Treatment of Nodal Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 1657-1657.	1.4	2
411	Current Treatment Patterns and Outcomes in Patients with Peripheral T-Cell Lymphoma: Updated Results of the Nationwide, Multi-Center Prospective Registry Study (CISL 1404). <i>Blood</i> , 2019, 134, 2844-2844.	1.4	2
412	Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 621-621.	1.4	2
413	Promising clinical efficacy and acceptable safety profile of sequential Pâ€GEMOX and radiotherapy for localized ENKTL. <i>Hematological Oncology</i> , 2022, 40, 341-342.	1.7	2
414	Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 641-648.	2.4	2

#	ARTICLE	IF	CITATIONS
415	Outcomes in Refractory Diffuse Large B-Cell Lymphoma: Results from Two Prospective Korean Cohorts. <i>Cancer Research and Treatment</i> , 2023, 55, 325-333.	3.0	2
416	Comprehensive comparison of international prognostic indexes for follicular helper T-cell lymphoma. <i>Annals of Hematology</i> , 0, , .	1.8	2
417	Outcomes of a Modified CALGB 19802 Regimen in Adult Acute Lymphoblastic Leukemia. <i>Journal of Korean Medical Science</i> , 2008, 23, 278.	2.5	1
418	Reply to K. Shimada et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e230-e230.	1.6	1
419	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
420	Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 1613-1613.	1.4	1
421	Multicenter Phase II Trial of 90Y-Ibritumomab Tiuxetan with High-Dose Chemotherapy (Busulfan/Cyclophosphamide/Etoposide) Followed by Autologous Stem Cell Transplantation in Relapsed, Refractoried, or High-Risk B-Cell NHL.. <i>Blood</i> , 2007, 110, 1914-1914.	1.4	1
422	Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma In Patients Treated with R-Chop; Consortium for Improving Survival of Lymphoma (CISL) Study.. <i>Blood</i> , 2010, 116, 1790-1790.	1.4	1
423	Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study. <i>Blood</i> , 2016, 128, 4194-4194.	1.4	1
424	Phase III study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS8612-TPS8612.	1.6	1
425	Intestinal Marginal Zone B-Cell Lymphoma of MALT Type: Clinical Manifestation and Outcome of a Rare Disease.. <i>Blood</i> , 2006, 108, 4742-4742.	1.4	1
426	Phase II Trial of 90y-Ibritumomab Tiuxetan Treatment as Consolidation After 6th R-CHOP Chemotherapy in Patients with Limited-Stage, Bulky Diffuse Large B Cell Lymphoma.. <i>Blood</i> , 2009, 114, 3751-3751.	1.4	1
427	Allogeneic Stem Cell Transplantation (alloSCT) and Donor Lymphocyte Infusion (DLI) In Patients with Non-Hodgkin Lymphoma (NHL) Who Experienced Relapse or Progression After Autologous Stem Cell Transplantation (autoSCT): Retrospective Analysis From the Korean Society of Blood and Marrow Transplantation. <i>Blood</i> . 2010. 116. 3536-3536.	1.4	1
428	Primary Gastrointestinal Follicular Lymphoma: Single-Center 12 Year Experiences. <i>Hepato-Gastroenterology</i> , 2011, 59, 751-3.	0.5	1
429	The Impact of Activated Akt Expression On Clinical Outcome in Diffuse Large B-Cell Lymphoma: A Clinicopathological Study of 99 Cases.. <i>Blood</i> , 2012, 120, 2676-2676.	1.4	1
430	Evaluation of biochemical features of anemia in cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20698-e20698.	1.6	1
431	A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> . 2018. 36. TPS2603-TPS2603.	1.6	1
432	Comparison of Efficacy and Safety of Biosimilar CT-P10 to Rituximab in Patients with Previously Untreated Low Tumor Burden Follicular Lymphoma (LTBFL): A Randomized Phase III Study. <i>Blood</i> , 2018, 132, 1596-1596.	1.4	1

#	ARTICLE	IF	CITATIONS
433	Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance. Korean Journal of Internal Medicine, 2020, 35, 194-204.	1.7	1
434	A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma. Blood, 2021, 138, 4362-4362.	1.4	1
435	Comprehensive Understanding of Gut Microbiota in Treatment Naïve Diffuse Large B Cell Lymphoma Patients. Blood, 2021, 138, 2409-2409.	1.4	1
436	Long-Term Efficacy and Safety (27 months) of the Biosimilar CT-P10 in Patients with Low Tumor Burden Follicular Lymphoma. Blood, 2020, 136, 27-28.	1.4	1
437	Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin's Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL). Cancer Research and Treatment, 2023, 55, 304-313.	3.0	1
438	Quantifying the Circulating Epstein-Barr Virus (EBV) DNA to Monitor a Case of Aggressive Natural Killer Cell Leukemia. The Korean Journal of Hematology, 2007, 42, 167.	0.7	0
439	Relapsed Intravascular Large B-cell Lymphoma in the Lungs. The Korean Journal of Hematology, 2008, 43, 113.	0.7	0
440	Extranodal NK/T-cell lymphoma presented as panniculitis of breast in a male patient: A case report. European Journal of Radiology Extra, 2011, 78, e105-e107.	0.1	0
441	IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S406-S407.	0.4	0
442	HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S371.	0.4	0
443	TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S411.	0.4	0
444	A Phase II Trial of UFT-E and Oral Leucovorin in Advanced Colorectal Cancer. Cancer Research and Treatment, 2001, 33, 225-228.	3.0	0
445	CHOP Followed by Radiotherapy for Localized Aggressive Primary Gastric Lymphoma: Results of a Multi Center Phase II Study.. Blood, 2004, 104, 3306-3306.	1.4	0
446	Primary Gastric T-Cell Lymphoma: Clinicopathologic Features and Treatment Outcome.. Blood, 2005, 106, 3355-3355.	1.4	0
447	Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma.. Blood, 2005, 106, 1491-1491.	1.4	0
448	Prospective Clinical Study of Surgical Resection Followed by CHOP in Localized Intestinal Lymphoma.. Blood, 2005, 106, 4743-4743.	1.4	0
449	Clinical Features and Treatment Outcomes of Primary Testicular Lymphoma.. Blood, 2006, 108, 4670-4670.	1.4	0
450	Frequent CD7 Antigen Loss in Aggressive Natural Killer-Cell Leukemia Can Be a Useful Diagnostic Marker.. Blood, 2007, 110, 2400-2400.	1.4	0

#	ARTICLE	IF	CITATIONS
451	A Multicenter Phase II Trial of Etoposide, Methylprednisolone, High-Dose Cytarabine, and Oxaliplatin (ESHAOX) for Patients with Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma.. Blood, 2007, 110, 3446-3446.	1.4	0
452	Nongastric Marginal Zone B-Cell Lymphoma: A Prognostic Model from a Retrospective Multicenter Study.. Blood, 2007, 110, 1361-1361.	1.4	0
453	Do Microenvironmental Factors Play Important Role in Supporting the Maintenance of Leukemic Stem Cells of Chronic Myelogenous Leukemia?. Blood, 2008, 112, 4219-4219.	1.4	0
454	Alemtuzumab and DHAP (A-DHAP) Is An Effective Salvage Therapy for Peripheral T-Cell Lymphoma, Unspecified: Interim Results of a Phase II Prospective Multicenter Study. Blood, 2008, 112, 5002-5002.	1.4	0
455	Central Nervous System (CNS) Relapse in Extranodal NK/T Cell Lymphoma, Nasal Type: When Do We Need CNS Prophylaxis in Patients with Extranodal NK/T Cell Lymphoma?. Blood, 2008, 112, 2833-2833.	1.4	0
456	Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.. Blood, 2009, 114, 5009-5009.	1.4	0
457	Clinical Features and Prognostic Relevance of Ovarian Involvement in Non-Hodgkin's Lymphoma: a Consortium for Improving Survival of Lymphoma (CISL) Report.. Blood, 2009, 114, 4999-4999.	1.4	0
458	Relapsed Marginal Zone B-Cell Lymphoma: Clinical Features and Treatment Outcome.. Blood, 2009, 114, 5017-5017.	1.4	0
459	Treatment Outcome and Quality of Life in Non-Hodgkin's Lymphoma of Intestine: a Multicenter Study of the Consortium for Improving Survival of Lymphoma (CISL).. Blood, 2009, 114, 4992-4992.	1.4	0
460	Side Population Cells of Human B-Cell Non-Hodgkin Lymphoma Cell Lines May Contain Lymphoma-Stem Cells Responsible for Lymphoma Initiation. Blood, 2010, 116, 3105-3105.	1.4	0
461	Dasatinib for Chronic Phase Chronic Myeloid Leukemia After Failure of Imatinib In Korean Patients.. Blood, 2010, 116, 4494-4494.	1.4	0
462	Intensified 1st Cycle Rituximab (R) Plus 8th Cycles of R-CHOP (cyclophosphamide, adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 31 B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis.. Blood, 2010, 116, 1786-1786.	1.4	0
463	Concurrent Chemo-Radiotherapy Followed by VIDL (Etoposide, Ifosfamide, Dexamethasone,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 31 Blood, 2010, 116, 1765-1765.	1.4	0
464	Aggressive NK Cell Leukemia (ANKL): Experience with 34 Patients and Therapeutic Potentials of L-Asparaginase and Allogeneic Hematopoietic Cell Transplantation - A Japan-Korea Multicenter Study for ANKL (ANKL07) -. Blood, 2010, 116, 3091-3091.	1.4	0
465	Waldeyer's Ring Marginal Zone B-Cell Lymphoma: Which Is Their Clinical and Prognostic Feature, Nodal or Extranodal?. Blood, 2010, 116, 5084-5084.	1.4	0
466	Stage I or II Marginal Zone B-Cell Lymphoma; Multicenter Retrospective Analysis of 217 Cases. Blood, 2011, 118, 5219-5219.	1.4	0
467	Relationship Between Intestinal Marginal Zone B-Cell Lymphoma and Enterobacterias Including Campylobacter Jejuni. Blood, 2011, 118, 5224-5224.	1.4	0
468	Busulfan, Melphalan and Etoposide Followed by Autologous Stem Cell Transplantation on Patients with Non-Hodgkin's Lymphoma: Multicenter Study From Consortium for Improving Survival of Lymphoma (CISL) in Korea. Blood, 2011, 118, 2021-2021.	1.4	0

#	ARTICLE	IF	CITATIONS
469	Acute Myeloid Leukemia with Myelodysplasia-Related Changes (MRC) Did Not Show Inferior Outcomes Compared to Those without MRC. Blood, 2011, 118, 3563-3563.	1.4	0
470	Baseline Quality of Life Assessed with the EORTC QLQ-C30 Predicts the Treatment Outcome of Patients with Diffuse Large B-Cell Lymphoma: Results of a Prospective Cohort Study. Blood, 2011, 118, 1595-1595.	1.4	0
471	A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL). Journal of Clinical Oncology, 2012, 30, 8029-8029.	1.6	0
472	The International Prognostic Index Is a Better Predictor of Thrombotic Complications Than the Khorana Score for Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: Results of a Single Center Prospective Cohort Study. Blood, 2012, 120, 5095-5095.	1.4	0
473	Prospective Cohort Study with Risk-Adapted Central Nervous System (CNS) Evaluation in Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Analysis of Incidence and Risk Factors for Secondary CNS Involvement. Blood, 2012, 120, 2683-2683.	1.4	0
474	Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma (NKL) and Maintenance Treatment May Be Essential for Sustained Response. Blood, 2012, 120, 3669-3669.	1.4	0
475	Clinical Characteristics and Outcomes Of Waldenstrom's Ring Lymphoma: Nation-Wide Study In Korea. Blood, 2013, 122, 4332-4332.	1.4	0
476	Weekly Four Times Rituximab Consolidation Following Reduced Cycles Of R-CHOP Induction Chemotherapy In Extremely Elderly Patients With Diffuse Large B Cell Lymphoma. Blood, 2013, 122, 3031-3031.	1.4	0
477	Neutropenic and Non-Neutropenic Fever In Diffuse Large B-Cell Lymphoma Patients Treated With Rituximab-CHOP Chemotherapy. Blood, 2013, 122, 5103-5103.	1.4	0
478	Clinical Outcomes of R-CHOP Chemotherapy Alone Compared with R-CHOP Plus Radiotherapy in Patients with Localized, Non-Bulky Diffuse Large B-Cell Lymphoma. Blood, 2014, 124, 4421-4421.	1.4	0
479	Clinical Relevance of CD45+/CD19- Stem-like Tumor Cells in Patients with Mantle Cell Lymphoma: A Single Center Experience. Blood, 2014, 124, 1622-1622.	1.4	0
480	Final Report on Phase II Trial of L-Asparaginase Plus Concurrent Chemoradiotherapy Followed By Midle (Methotrexate, Ifosfamide, Etoposide, Dexamethasone, and L-asparaginase) Chemotherapy for Patients with Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma, Nasal Type. Blood, 2015, 126, 3942-3942.	1.4	0
481	Randomized Trial of Micafungin Versus Fluconazole in Prophylaxis Against Invasive Fungal Infections in Hematopoietic Stem Cell Transplant Recipients. Blood, 2015, 126, 1904-1904.	1.4	0
482	Clinical Relevance of Failure to Achieve Early Molecular Response in Chronic Myeloid Leukemia in Chronic Phase. Blood, 2015, 126, 5160-5160.	1.4	0
483	Prevalence and Prognostic Impact of CD30 and EBV Co-Expression in Korean Patients with EBV-Positive DLBCL of the Elderly. Blood, 2015, 126, 5021-5021.	1.4	0
484	Exome Sequencing of Aggressive Natural Killer Cell Leukemia and Drug Profiling Highlight Candidate Driver Pathways in Malignant Natural Killer Cells. Blood, 2015, 126, 700-700.	1.4	0
485	Mutational Landscape of Aggressive Natural Killer Cell Leukemia and Drug Sensitivity Profiling Reveal Therapeutic Options in Natural Killer Cell Malignancies. Blood, 2016, 128, 2921-2921.	1.4	0
486	A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-Cell Lymphoma (BENCART): A Consortium for Improving Survival of Lymphoma (CISL) Trial. Blood, 2016, 128, 1823-1823.	1.4	0

#	ARTICLE	IF	CITATIONS
487	Randomized Phase II Multi-Center Trial of Busulfan, Etoposide, and Cyclophosphamide Versus Busulfan, Etoposide, and Melphalan As Conditioning Therapy for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma: A Multicenter Study from Consortium for Improving Survival of Lymphoma (CISL). <i>Blood</i> , 2016, 128, 3466-3466.	1.4	0
488	A proposal for a new staging system for extranodal natural killer T-cell lymphoma, nasal type, to predict the treatment strategy: A multicentre study from the Chinese Southwest Oncology Group and Asia Lymphoma Study Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7552-7552.	1.6	0
489	Clinical Relevance of Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH) and Survival Outcome of Adult HLH Patients: A Single-Center Prospective Cohort Study. <i>Blood</i> , 2018, 132, 3718-3718.	1.4	0
490	Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study. <i>Blood</i> , 2019, 134, 4076-4076.	1.4	0
491	A Phase 1/1b Dose-Escalation Trial Evaluating Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, in Subjects with Relapsed/Refractory T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4030-4030.	1.4	0
492	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. <i>Blood</i> , 2019, 134, 2847-2847.	1.4	0
493	Clinical Application of Circulating Tumor DNA in Plasma of Patients with Primary Central Nervous System Lymphoma. <i>Blood</i> , 2019, 134, 1491-1491.	1.4	0
494	404â€¦ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC). , 2020, , .		0
495	Clinical outcomes of early-progressed follicular lymphoma in Korea: a multicenter, retrospective analysis. <i>Archives of Medical Science</i> , 0, , .	0.9	0
496	Asia subpopulation analysis from the phase III POLARIX trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7558-7558.	1.6	0